Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Purified recombinant fragment of human CD105 expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:200 - 1:400|
|Immunocytochemistry (ICC)||1:200 - 1:1000|
|Immunofluorescence (IF)||1:200 - 1:1000|
|Immunohistochemistry (IHC)||1:200 - 1:1000|
|Western Blot (WB)||1:500 - 1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
MA5-17041 targets CD105 in FACS, ICC, IF, IHC, and WB applications and shows reactivity with Human samples.
The MA5-17041 immunogen is purified recombinant fragment of human CD105 expressed in E. Coli.
MA5-17041 detects CD105 which has a predicted molecular weight of approximately 71kDa.
This gene encodes a homodimeric transmembrane protein which is a major glycoprotein of the vascular endothelium. This protein is a component of the transforming growth factor beta receptor complex and it binds TGFB1 and TGFB3 with high affinity. Mutations in this gene cause hereditary hemorrhagic telangiectasia, also known as Osler-Rendu-Weber syndrome 1, an autosomal dominant multisystemic vascular dysplasia.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.
MA5-17041 was used in immunohistochemistry to study the value of CD105, VEGF and sFLT1 in predicting the presence of metastases in endometrioid endometrial carcinoma
|Saarelainen SK,Staff S,Peltonen N,Lehtimäki T,Isola J,Kujala PM,Vuento MH,Mäenpää JU||Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (35:4651)||2014|
CD105; CD105 antigen; END; ENG; HHT1; ORW; ORW1
END; ENG; HHT1; ORW1